Autopsy report · NCT02749825

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

“Withdrawal of funding support”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 years 8 months after it had already started.
• Ran for about 3 years 10 months before it stopped.
• 41 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Pharmatech

Sponsor type

Industry

Conditions

Prostate Cancer

Interventions

Trelstar; Lupron; Zoladex

Participants

41

Sites

11

Countries

United States

Trials that died the same way

• Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
  “Withdrawal of funding” (91% match in meaning)
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
  “Funding withdrawal” (90% match in meaning)
• Post Hysterectomy Pain Prevention: Pre-op Wound Infiltration With Anesthetic Protocol Versus Standard of Care
  “Funding withdrawn” (85% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (81% match in meaning)
• BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
  “Withdrawal of sponsor support” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.